最新ニュース 10x Genomics (NASDAQ:TXG) 株価情報

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

<ul>
<li>Approximately 1% domestic same store sales growth, previously low- to mid- single digits;</li>
<li>Global unit growth rate of 16% to 17%, previously 14% to 15%;</li>
<li>SG&amp;A of approximately $140 million, which includes system implementation costs of approximately $4.5 million;</li>
<li>Stock-based compensation expense of approximately $26 million;</li>
<li>Interest expense, net of approximately $40 million, previously approximately $46 million; and</li>
<li>Depreciation and amortization of between $28 and $29 million, previously $29 - $30 million.</li>
</ul>

News

Guidance

WING

Wingstop Sees FY25 Same Store Sales Growth ~1%

Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/META/earnings">closing bell on Wednesday, April 30.</a>
Analysts expect the Menlo Park, California-based company to report quarterly earnings at $5.22 per share, up from $4.71 per share in the year-ago period. Meta projects to report quarterly revenue at $41.36 billion, compared to $36.45 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The social media and technology company has beaten analyst estimates for revenue in 10 straight quarters.
Meta shares gained 0.9% to close at $554.44 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/META/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Mark Kelley maintained a Buy rating and cut the price target from $740 to $628 on April 23, 2025. This analyst has an accuracy rate of 83%.</li>
<li>Needham analyst Laura Martin reiterated an Underperform rating on April 23, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Truist Securities analyst Youssef Squali maintained a Buy rating and cut the price target from $770 to $700 on April 17, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Cantor Fitzgerald analyst Deepak Mathivanan maintained an Overweight rating and cut the price target from $790 to $624 on April 16, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Wedbush analyst Meta Marshall maintained an Outperform rating and cut the price target from $770 to $680 on April 15, 2025. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-1024x600.png" alt="" class="wp-image-894197" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

Top Wall Street Forecasters Revamp Meta Platforms Expectations Ahead Of Q1 Earnings

Ontrak, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, announced it has been re-certified by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) for the element of license to practice. This re-certification reaffirms Ontrak's ongoing commitment to maintaining the highest standards of quality and compliance across its suite of healthcare solutions, helping health plan customers effectively meet their accreditation goals.
NCQA, a recognized leader in healthcare quality assessment, evaluation, and certification, grants this prestigious re-certification after a voluntary review process and evaluation of a CVO's management of various aspects of its data collection and verification operation, and the process it uses to continuously improve the services it provides.
"This re-certification is more than a compliance milestone, it's a reflection of our unwavering commitment to trust, transparency, and operational excellence." said Brandon LaVerne, Chief Executive Officer and Chief Operating Officer at Ontrak. "At Ontrak health, we anchor our identity around the impact we deliver, and this recognition reinforces the confidence our partners, members, and health plan customers place in us every day."
"Achieving CVO certification from NCQA demonstrates that Ontrak Health has the systems, process and personnel in place to thoroughly and accurately verify providers' credentials and help health plan clients meet their accreditation goals," commented Margaret E. O'Kane, President of the NCQA.

OTRK

Ontrak Announces It Has Been Re-Certified By The National Committee For Quality Assurance As A Credentials Verification Organization For the Element of License To Practice.

Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) affirms FY2025 GAAP EPS guidance from $10.15-$10.55 to $10.15-$10.55 vs $10.27 analyst estimate..

Illinois Tool Works Affirms FY2025 GAAP EPS Guidance of $10.15-$10.55 vs $10.27 Est

Rosenblatt analyst Barton Crockett maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Neutral and lowers the price target from $658 to $657.

SPOT

Rosenblatt Maintains Neutral on Spotify Technology, Lowers Price Target to $657

INEO

INNEOVA Holdings Completes Acquisition Of INNEOVA Engineering Pte. Ltd.

VXRT

Vaxart Completes Enrollment Of Phase 1 Clinical Trial Evaluating Second-generation Oral Norovirus Vaccine Constructs Head-To-Head Against First-generation Constructs; Topline Data Expected In Mid-2025

CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.49 by 10.2 percent. This is a 6.38 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $125.77 million which missed the analyst consensus estimate of $128.72 million by 2.29 percent. This is a 0.02 percent increase over sales of $125.75 million the same period last year.

Earnings Misses

CTS Q1 Adj. EPS $0.44 Misses $0.49 Estimate, Sales $125.77M Miss $128.72M Estimate

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization
Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures
CeriBell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) ("Ceribell"), a medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that its point-of-care electroencephalogram (EEG) system has received full FedRAMP&#xAE; (Federal Risk and Authorization Management Program) High authorization from the U.S. government. This elite cybersecurity authorization is awarded to organizations that meet the government's highest security requirements. Ceribell's secure, cloud-based solution can now be adopted across federal healthcare systems, expanding access to rapid diagnosis of non-convulsive seizures for U.S. veterans and other high-risk patients. As of April 28, 2025, only 51 companies in the U.S. have achieved High authorization, and there are no other medical device companies on that list.
Designed for rapid setup and continuous brain monitoring, the Ceribell system is already in use at hospitals within the Department of Veterans Affairs (VA) after receiving Authority to Operate (ATO) in 2024. Now, FedRAMP High authorization paves the way for broader implementation throughout federal healthcare agencies, including the entire VA system, enabling more efficient deployment and secure data sharing between facilities. Achievement of this designation further establishes Ceribell as a trusted partner to health systems and validates its commitment to securing patient data while enhancing patient care.

CBLL

Ceribell Announces FedRAMP High Authorization, Expanding Approval For Its AI-Powered Point-Of-Care EEG Across Federal Healthcare Systems

Avnet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) is looking for Q4 GAAP EPS of $0.47-$0.66 vs $0.74 analyst estimate..

Avnet Sees Q4 GAAP EPS $0.47-$0.66 vs $0.74 Est

Hess Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESM#NYSE">HESM</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.57 by 14.04 percent. This is a 10.17 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $382.00 million which beat the analyst consensus estimate of $381.62 million by 0.10 percent. This is a 7.42 percent increase over sales of $355.60 million the same period last year.

Earnings Beats

HESM

Hess Midstream Q1 EPS $0.65 Beats $0.57 Estimate, Sales $382.00M Beat $381.62M Estimate

During the last three months, 4 analysts shared their evaluations of Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Beyond, revealing an average target of $9.12, a high estimate of $16.00, and a low estimate of $5.00. Highlighting a 25.18% decrease, the current average has fallen from the previous average price target of $12.19. 
<img src="https://www.benzinga.com/files/images/story/2025/1746014498_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Beyond. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Matuszewski</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$6.50</td>
</tr>
<tr>
<td>Jonathan Matuszewski</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.50</td>
<td>$7.25</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Tom Forte</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beyond. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Beyond compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Beyond's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Beyond's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BYON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Beyond analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Beyond: A Closer Look</h2>
Beyond Inc is an online retailer that provides products and services through websites. The company offers a broad number of products, including furniture, decor, area rugs, bedding and bath, home improvement, outdoor, and kitchen and dining items, BMMG (like books, magazines, CDs), electronics, and other items. The home and garden product line accounts for a material part of its total revenue. The company operates through a direct business that makes sales from the company's own inventory, and a partner business that sells merchandise from manufacturers, distributors, and other suppliers through the company's websites. The company generates the majority of its total revenue from partner business in terms of business format, and from the U.S. in terms of market.
<h3>Beyond: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Beyond's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -21.15%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Beyond's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -26.8%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Beyond's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -45.28%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Beyond's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -19.57%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BYON

Analyst Expectations For Beyond's Future

Wingstop Q1 EPS $0.99 Beats $0.90 Estimate, Sales $171.10M Beat $170.92M Estimate

RGTI

Rigetti Computing Closes Previously Announces Investment By Quanta Computer

Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.73 by 4.11 percent. This is a 18.75 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $463.80 million which beat the analyst consensus estimate of $462.62 million by 0.25 percent. This is a 9.16 percent increase over sales of $424.90 million the same period last year.

Federal Signal Q1 Adj. EPS $0.76 Beats $0.73 Estimate, Sales $463.80M Beat $462.62M Estimate

Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) reported quarterly earnings of $2.38 per share which beat the analyst consensus estimate of $2.36 by 0.85 percent. This is a 2.46 percent decrease over earnings of $2.44 per share from the same period last year. The company reported quarterly sales of $3.84 billion which met the analyst consensus estimate. This is a 3.37 percent decrease over sales of $3.97 billion the same period last year.

Illinois Tool Works Q1 EPS $2.38 Beats $2.36 Estimate, Sales $3.84B Inline

Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">11</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Visa and provided 12-month price targets. The average target is $383.53, accompanied by a high estimate of $410.00 and a low estimate of $330.00. This upward trend is apparent, with the current average reflecting a 7.17% increase from the previous average price target of $357.88.
<img src="https://www.benzinga.com/files/images/story/2025/1746014488_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Visa's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$384.00</td>
<td>$383.00</td>
</tr>
<tr>
<td>Adam Frisch</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$330.00</td>
<td>-</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$410.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$396.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$359.00</td>
<td>$304.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$383.00</td>
<td>$368.00</td>
</tr>
<tr>
<td>Andrew Schmidt</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$393.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Matthew O'Neill</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>John Davis</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$393.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$395.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Jason Kupferberg</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$363.00</td>
<td>$331.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Visa. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Visa compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Visa's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Visa's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/V/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Visa analyst ratings.</a>
<h2>All You Need to Know About Visa</h2>
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
<h3>Understanding the Numbers: Visa's Finances</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Visa's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.15%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Visa's net margin is impressive, surpassing industry averages. With a net margin of 53.83%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Visa's ROE stands out, surpassing industry averages. With an impressive ROE of 13.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Visa's ROA stands out, surpassing industry averages. With an impressive ROA of 5.49%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.55.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Visa In The Eyes Of 17 Experts

Avnet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) is looking for Q4 Adj EPS of $0.65-$0.75 vs $0.90 analyst estimate. sees sales of $5.150 billion-$5.450 billion vs $5.46 billion analyst estimate.

Avnet Sees Q4 Adj EPS $0.65-$0.75 vs $0.90 Est; Sees Sales $5.150B-$5.450B vs $5.46B Est

Ratings for Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $335.6, a high estimate of $425.00, and a low estimate of $232.00. Observing a downward trend, the current average is 17.85% lower than the prior average price target of $408.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746014470_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Zebra Technologies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$325.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Piyush Avasthy</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$371.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$232.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$254.00</td>
<td>$379.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$425.00</td>
<td>$445.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$432.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$379.00</td>
<td>$409.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$326.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$390.00</td>
<td>$427.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$395.00</td>
<td>$430.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zebra Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zebra Technologies compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zebra Technologies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Zebra Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZBRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zebra Technologies analyst ratings.</a>
<h2>Get to Know Zebra Technologies Better</h2>
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
<h3>Understanding the Numbers: Zebra Technologies's Finances</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Zebra Technologies's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 32.21%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Zebra Technologies's net margin excels beyond industry benchmarks, reaching 12.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zebra Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Zebra Technologies's ROA stands out, surpassing industry averages. With an impressive ROA of 2.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Zebra Technologies's debt-to-equity ratio surpasses industry norms, standing at 0.66. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZBRA

What 10 Analyst Ratings Have To Say About Zebra Technologies

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and maintains $130 price target.

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Maintains $130 Price Target

Press Releases

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

BRKR

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

ニュース

最新ニュース 10x Genomics (NASDAQ:TXG) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル